Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma.

Hsu CL, Chan SC, Chang KP, Lin TL, Lin CY, Hsieh CH, Huang SF, Tsang NM, Lee LY, Ng SH, Wang HM.

Oral Oncol. 2013 Jun;49(6):620-5. doi: 10.1016/j.oraloncology.2013.02.006. Epub 2013 Mar 5.

PMID:
23466197
2.

Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.

Wang WY, Twu CW, Lin WY, Jiang RS, Liang KL, Chen KW, Wu CT, Shih YT, Lin JC.

Cancer. 2011 Oct 1;117(19):4452-9. doi: 10.1002/cncr.26069. Epub 2011 Mar 22.

3.

Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study.

Mäkitie AA, Reis PP, Irish J, Zhang T, Chin SF, Chen X, Marriott C, Keller A, Perez-Ordonez B, Kamel-Reid S, Siu LL.

Head Neck. 2004 Sep;26(9):815-22.

PMID:
15350028
4.

[Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].

Hou X, Zhang L, Zhao C, Li S, Lu LX, Han F, Shao JY, Huang PY.

Ai Zheng. 2006 Jul;25(7):785-92. Chinese.

PMID:
16831265
5.
6.

Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.

Shen T, Tang LQ, Luo DH, Chen QY, Li PJ, Mai DM, Guo SS, Liu LT, Qian CN, Guo X, Zeng MS, Mo HY, Mai HQ.

PLoS One. 2015 Apr 8;10(4):e0122756. doi: 10.1371/journal.pone.0122756. eCollection 2015.

7.

Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma.

Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ.

J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9.

PMID:
12419787
8.

Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.

Kalpoe JS, Dekker PB, van Krieken JH, Baatenburg de Jong RJ, Kroes AC.

J Clin Pathol. 2006 May;59(5):537-41. Epub 2006 Feb 17.

9.

Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.

Chan KC, Hung EC, Woo JK, Chan PK, Leung SF, Lai FP, Cheng AS, Yeung SW, Chan YW, Tsui TK, Kwok JS, King AD, Chan AT, van Hasselt AC, Lo YM.

Cancer. 2013 May 15;119(10):1838-44. doi: 10.1002/cncr.28001. Epub 2013 Feb 21.

10.
11.

Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.

Ji MF, Huang QH, Yu X, Liu Z, Li X, Zhang LF, Wang P, Xie SH, Rao HL, Fang F, Guo X, Liu Q, Hong MH, Ye W, Zeng YX, Cao SM.

Cancer. 2014 May 1;120(9):1353-60. doi: 10.1002/cncr.28564. Epub 2014 Jan 29.

12.

[Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].

Cao SM, Min HQ, Gao JS, Hong MH, Xiao XB, Zhang CQ, Liu XD, Zhang AL, Guo X.

Ai Zheng. 2003 Mar;22(3):302-6. Chinese.

PMID:
12654192
13.

Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma.

Yip TT, Ngan RK, Fong AH, Law SC.

Oral Oncol. 2014 Jun;50(6):527-38. doi: 10.1016/j.oraloncology.2013.12.011. Epub 2014 Jan 15. Review.

PMID:
24440146
14.

Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.

Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, Wang JY, Twu CW, Liang KL, Chao J, Shen WC.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1342-8. Epub 2007 Apr 20.

PMID:
17449194
15.

Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study.

Liang FY, Sun W, Han P, Lu X, Lian YN, Huang XM.

Chin J Cancer. 2012 Mar;31(3):142-9. doi: 10.5732/cjc.011.10279. Epub 2012 Jan 9.

17.

Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging.

Tang LQ, Chen QY, Fan W, Liu H, Zhang L, Guo L, Luo DH, Huang PY, Zhang X, Lin XP, Mo YX, Liu LZ, Mo HY, Li J, Zou RH, Cao Y, Xiang YQ, Qiu F, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Mai HQ.

J Clin Oncol. 2013 Aug 10;31(23):2861-9. doi: 10.1200/JCO.2012.46.0816. Epub 2013 Jul 15. Erratum in: J Clin Oncol. 2016 Feb 10;34(5):519.

PMID:
23857969
19.

Epstein-Barr virus DNA measured in nasopharyngeal brushings in patients with nasopharyngeal carcinoma: pilot study.

Mäkitie AA, Reis PP, Zhang T, Chin SF, Gullane P, Siu LL, Kamel-Reid S, Irish J.

J Otolaryngol. 2004 Oct;33(5):299-303.

PMID:
15931814
20.

Supplemental Content

Support Center